From Data to Treatment: Medidata's Fareed Melhem Discusses AI's Impact on Clinical Trials
As the potential of artificial intelligence (AI) continues to unfold, how is it revolutionizing the intricate landscape of clinical trials? How can vast reservoirs of data be harnessed to enhance patient experiences and accelerate drug discovery? Navigating the maze of global regulations presents its own challenges, but can these be surmounted with technological innovation? And in an era that emphasizes the importance of diversity and inclusion, how can we ensure that clinical trials truly reflect the diverse populations they serve?
In order to answer these and some other questions regarding the growing role of AI in clinical trials, I have talked to Fareed Melhem, Senior VP and Head of AI at Medidata, a Dassault Systèmes company.
Medidata, a provider of clinical trial solutions to the life sciences industry, recently announced a multi-year partnership expansion with Catalyst Clinical Research to support their global oncology brand, Catalyst Oncology. Through this extended partnership, Catalyst can continue to support over 150 oncology studies and manage more than 80 next-generation cancer clinical trials today across Phase I-III. Notably, around 90% of all oncology FDA approvals last year were developed using Medidata software.
Topics: Clinical Trials